Page 33 - MBCA_FULL REPORT_FINAL_FOR_WEB

Funded Research Grants Analysis

Information on research grants awarded by most major cancer and biomedical research
funding organizations was extracted from 2 databases: the International Cancer Research
Partnership (ICRP) database and the Health Research Alliance (HRA) database.

Established in 2000, the ICRP is a unique alliance of cancer research funding organizations
[9]
working together to enhance global collaboration and strategic coordination of research .
The ICRP aims to improve access to information about cancer research being conducted
and enable cancer funding organizations to maximize the impact of their independent
efforts for the benefit of researchers and cancer patients worldwide. The ICRP includes
organizations from Australia, Canada, France, Japan, the Netherlands, United Kingdom, and
US. ICRP member organizations share funding information in a common format (known as
the Common Scientific Outline [CSO]) to facilitate the pooling and evaluation of data across
organizations [10-12] . The database includes grants from both government and private, nonprofit
cancer research funding organizations from within the ICRP member countries, including the
US National Institutes of Health. (For a complete list of ICRP members and CSO codes, see
www.icrpartnership.org.)

Figure 2: Steps in Metastasis Framework by Steeg , Used For Grants
[6]

osteoclasts
osteoblasts
fibroblasts
hematopoietic progenitors
kupffer cells
glial cells
astrocytes
endothelial cells
immune cells

dormancy
invasion
dormancy
intravasation, arrest and
extravasation angiogenesis

metastatic colonization

Abbreviations: BH3 = pro-apoptotic member of the Bcl-2 protein family;
anti-CTLA4 mAb = anti–cytotoxic T-lymphocyte-associated protein 4
monoclonal antibody; EFGR = another term for ErbB, the epidermal
growth factor receptor protein family, , HGF/c-Met = hepatocyte growth
factor/MET proto-oncogene, receptor tyrosine kinase; PARP = poly-ADP
ribose polymerase, VEGF = vascular endothelial growth factor. 33